This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 50 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
CD80
宿主: 小鼠
宿主: HEK-293 Cells
Recombinant
>95 % as determined by SDS-PAGE.
Active
限制
仅限研究用
状态
Lyophilized
缓冲液
50 mM Tris, 100 mM Glycine, pH 7.5
注意事项
Please avoid repeated freeze-thaw cycles.
储存条件
-20 °C
储存方法
No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
Ganesan, Moon, Barakat: "Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study." in: Biochimica et biophysica acta. General subjects, Vol. 1862, Issue 12, pp. 2764-2778, (2019) (PubMed).
Ganesan, Ahmed, Okoye, Arutyunova, Babu, Turnbull, Kundu, Shields, Agopsowicz, Xu, Tabana, Srivastava, Zhang, Moon, Belovodskiy, Hena, Kandadai, Hosseini, Hitt, Walker, Smylie, West, Siraki, Lemieux et al.: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." in: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).
Gmyrek, Pingel, Choi, Green: "Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma." in: Cellular immunology, Vol. 319, pp. 28-34, (2017) (PubMed).
B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20 - 100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.